Masaki Mandai

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9302027/publications.pdf

Version: 2024-02-01

126907 49909 8,120 126 33 87 citations h-index g-index papers 131 131 131 12050 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Placental functional assessment and its relationship to adverse pregnancy outcome: comparison of intravoxel incoherent motion (IVIM) MRI, T2-relaxation time, and umbilical artery Doppler ultrasound. Acta Radiologica, 2023, 64, 370-376.	1.1	1
2	Chronic abruption-oligohydramnios sequence (CAOS) revisited: possible implication of premature rupture of membranes. Journal of Maternal-Fetal and Neonatal Medicine, 2022, 35, 6894-6900.	1.5	2
3	Lower systolic blood pressure levels in early pregnancy are associated with a decreased risk of early-onset superimposed preeclampsia in women with chronic hypertension: a multicenter retrospective study. Hypertension Research, 2022, 45, 135-145.	2.7	12
4	Laparoscopic hysterectomy for endometrial cancer after the Fontan procedure: The first case report. International Cancer Conference Journal, 2022, 11, 41-45.	0.5	0
5	Radiomic machine learning for pretreatment assessment of prognostic risk factors for endometrial cancer and its effects on radiologists' decisions of deep myometrial invasion. Magnetic Resonance Imaging, 2022, 85, 161-167.	1.8	17
6	Aplastic Anemia Treated with Eltrombopag during Pregnancy. Case Reports in Obstetrics and Gynecology, 2022, 2022, 1-4.	0.3	0
7	The significance of clinical symptoms of subchorionic hematomas, "bleeding firstâ€, to stratify the high-risk subgroup of very early preterm delivery. Taiwanese Journal of Obstetrics and Gynecology, 2022, 61, 243-248.	1.3	7
8	The effect of celecoxib for treatment of preterm labor on fetuses during the second trimester of pregnancy: A pilot case series. Taiwanese Journal of Obstetrics and Gynecology, 2022, 61, 277-281.	1.3	7
9	Immunosuppressive tumor microenvironment in Uterine Serous Carcinoma via CCL7 signal with myeloid-derived suppressor cells. Carcinogenesis, 2022, , .	2.8	2
10	Analysis of postoperative adjuvant therapy in 102 patients with gastric-type mucinous carcinoma of the uterine cervix: A multi-institutional study. European Journal of Surgical Oncology, 2022, , .	1.0	4
11	CXCL13-producing CD4+ T cells accumulate in the early phase of tertiary lymphoid structures in ovarian cancer. JCl Insight, 2022, 7, .	5.0	48
12	Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types. JCO Precision Oncology, 2022, , .	3.0	18
13	Three cases of seromucinous carcinoma of the ovary arising in endometriotic cysts. International Cancer Conference Journal, 2021, 10, 46-53.	0.5	0
14	Intracervical elastomeric sealant in an ex vivo model. Journal of Maternal-Fetal and Neonatal Medicine, 2021, 34, 1109-1111.	1.5	2
15	Signaling and Drug Resistance. Current Human Cell Research and Applications, 2021, , 79-94.	0.1	O
16	Primary and recurrent serous borderline tumors during pregnancy: a case report and literature review. International Cancer Conference Journal, 2021, 10, 160-169.	0.5	3
17	Oncofertility care in young women and the outcomes of pregnancy over the last 5Âyears. Future Science OA, 2021, 7, FSO680.	1.9	4
18	Acquired Evolution of Mitochondrial Metabolism Regulated by HNF1B in Ovarian Clear Cell Carcinoma. Cancers, 2021, 13, 2413.	3.7	8

#	Article	IF	CITATIONS
19	Third trimester fetal death in heterotopic cervical pregnancy: a case report and literature review. Hypertension Research in Pregnancy, 2021, 9, 40-45.	0.2	O
20	Sebaceous carcinoma of the vulva treated with sentinel lymph node biopsy: a case report and literature review. International Cancer Conference Journal, 2021, 10, 239-243.	0.5	5
21	Combination of gene set signatures correlates with response to nivolumab in platinum-resistant ovarian cancer. Scientific Reports, 2021, 11, 11427.	3.3	3
22	A Case of Torsion in an Otherwise-Normal Ovary with a Giant Hematosalpinx Larger than Enlarged Ovary: Utilization of Diagnostic Laparoscopy for the Accurate Diagnosis. Case Reports in Obstetrics and Gynecology, 2021, 2021, 1-5.	0.3	0
23	A 36 kg Giant Ovarian Fibroma with Meigs Syndrome: A Case Report and Literature Review of Extremely Giant Ovarian Tumor. Case Reports in Obstetrics and Gynecology, 2021, 2021, 1-8.	0.3	4
24	Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types. JCO Precision Oncology, 2021, 5, 1270-1280.	3.0	9
25	PDK2 leads to cisplatin resistance through suppression of mitochondrial function in ovarian clear cell carcinoma. Cancer Science, 2021, 112, 4627-4640.	3.9	15
26	Differentiation of uterine low-grade endometrial stromal sarcoma from rare leiomyoma variants by magnetic resonance imaging. Scientific Reports, 2021, 11, 19124.	3.3	5
27	Superradical Hysterectomy for Cervical Cancer as an Alternative to the Usual Okabayashi-Type Radical Hysterectomy. The Surgery Journal, 2021, 7, S108-S114.	0.7	0
28	Fertility preservation of polypoid endometriosis: Case series and literature review. Journal of Obstetrics and Gynaecology Research, 2021, , .	1.3	4
29	Association between hospital treatment volume and survival of women with gynecologic malignancy in Japan: a JSOG tumor registry-based data extraction study. Journal of Gynecologic Oncology, 2021, 33,	2.2	4
30	Novel subtype of atonic postpartum hemorrhage: dynamic computed tomography evaluation of bleeding characteristics and the uterine cavity. Journal of Maternal-Fetal and Neonatal Medicine, 2020, 33, 3286-3292.	1.5	12
31	A National Survey of Umbilical Endometriosis in Japan. Journal of Minimally Invasive Gynecology, 2020, 27, 80-87.	0.6	17
32	Intratumor heterogeneity and homologous recombination deficiency of high-grade serous ovarian cancer are associated with prognosis and molecular subtype and change in treatment course. Gynecologic Oncology, 2020, 156, 415-422.	1.4	28
33	Conservative management for retained products of conception after less than 22 weeks of gestation. Journal of Obstetrics and Gynaecology Research, 2020, 46, 1982-1987.	1.3	10
34	Two Cases of Ectopic Pregnancy Mimicking Gestational Trophoblastic Disease. Case Reports in Obstetrics and Gynecology, 2020, 2020, 1-4.	0.3	3
35	Predictive factors for flares of established stable systemic lupus erythematosus without anti-phospholipid antibodies during pregnancy. Journal of Maternal-Fetal and Neonatal Medicine, 2020, , 1-6.	1.5	3
36	Mechanisms of thrombin-Induced myometrial contractions: Potential targets of progesterone. PLoS ONE, 2020, 15, e0231944.	2.5	15

#	Article	IF	Citations
37	Cancers associated with extraovarian endometriosis at less common/rare sites: A nationwide survey in Japan. Journal of Obstetrics and Gynaecology Research, 2020, 46, 917-923.	1.3	6
38	Anti-VEGF therapy resistance in ovarian cancer is caused by GM-CSF-induced myeloid-derived suppressor cell recruitment. British Journal of Cancer, 2020, 122, 778-788.	6.4	61
39	<i>HER2</i> â€amplified cervical gastricâ€type mucinous carcinoma with a primitive enterocyte phenotype. Histopathology, 2020, 77, 511-513.	2.9	2
40	Modified Mississippi protocol for HELLP/partial HELLP syndrome occurring in the periviable period: A report of three cases. Hypertension Research in Pregnancy, 2020, 8, 22-25.	0.2	0
41	Cushing's syndrome during pregnancy with different clinical courses: Two case reports. Hypertension Research in Pregnancy, 2020, 8, 26-30.	0.2	0
42	Mechanisms of thrombin-Induced myometrial contractions: Potential targets of progesterone., 2020, 15, e0231944.		0
43	Mechanisms of thrombin-Induced myometrial contractions: Potential targets of progesterone. , 2020, 15, e0231944.		0
44	Mechanisms of thrombin-Induced myometrial contractions: Potential targets of progesterone., 2020, 15, e0231944.		0
45	Mechanisms of thrombin-Induced myometrial contractions: Potential targets of progesterone. , 2020, 15, e0231944.		0
46	Mucinous adenocarcinoma, gastric type of the uterine cervix: clinical features and HER2 amplification. Medical Molecular Morphology, 2019, 52, 52-59.	1.0	25
47	Magnetic resonance relaxometry improves the accuracy of conventional MRI in the diagnosis of endometriosis‑associated ovarian cancer: A case report. Molecular and Clinical Oncology, 2019, 11, 296-300.	1.0	4
48	Analytical performance of a new automated chemiluminescent magnetic immunoassays for soluble PD-1, PD-L1, and CTLA-4 in human plasma. Scientific Reports, 2019, 9, 10144.	3.3	29
49	Novel intrauterine balloon tamponade systems for postpartum hemorrhage. Acta Obstetricia Et Gynecologica Scandinavica, 2019, 98, 1612-1617.	2.8	8
50	Severe fatty liver of pregnancy requiring an extremely large amount of blood transfusion, surgery and transarterial embolization: A case report. Case Reports in Women's Health, 2019, 23, e00130.	0.5	1
51	Placental Sonic Hedgehog Pathway Regulates Fetal Growth via the IGF Axis in Preeclampsia. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4239-4252.	3.6	17
52	Association between preterm delivery and bacterial vaginosis with or without treatment. Scientific Reports, 2019, 9, 509.	3.3	48
53	Analysis of gastric-type mucinous carcinoma of the uterine cervix — An aggressive tumor with a poor prognosis: A multi-institutional study. Gynecologic Oncology, 2019, 153, 13-19.	1.4	89
54	AOFOG survey for the status of minimally invasive gynecologic surgery in the Asia/Oceania region. Journal of Obstetrics and Gynaecology Research, 2019, 45, 1091-1095.	1.3	1

#	Article	IF	CITATIONS
55	The mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin than to conventional taxane and carboplatin chemotherapy in high grade serous ovarian carcinoma: A survey of Japanese Gynecologic Oncology Group study (JGOG3016A1). Gynecologic Oncology, 2019, 153, 312-319.	1.4	17
56	Clinical Determinants Affecting Indications for Surgery and Chemotherapy in Recurrent Ovarian Granulosa Cell Tumor. Healthcare (Switzerland), 2019, 7, 145.	2.0	3
57	VISTA expressed in tumour cells regulates T cell function. British Journal of Cancer, 2019, 120, 115-127.	6.4	133
58	Japan Society of Gynecologic Oncology guidelines 2017 for the treatment of uterine cervical cancer. International Journal of Clinical Oncology, 2019, 24, 1-19.	2.2	106
59	Video image: Ultrasound findings of a novel subtype of atonic postpartum hemorrhage: is it still a diagnosis of exclusion?. Hypertension Research in Pregnancy, 2019, 7, 39-40.	0.2	4
60	The efficacy of secondary cytoreductive surgery for recurrent ovarian, tubal, or peritoneal cancer in Tian-model low-risk patients. Journal of Gynecologic Oncology, 2019, 30, e100.	2.2	9
61	Laparoscopic conservative surgery for bilateral massive ovarian edema presenting with hemoperitoneum. Japanese Journal of Gynecologic and Obstetric Endoscopy, 2019, 35, 119-122.	0.0	O
62	Tight systolic blood pressure control early in pregnancy improves pregnancy outcomes in women with chronic hypertension. Hypertension Research in Pregnancy, 2019, 7, 75-81.	0.2	3
63	Snail promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via CXCR2 ligand upregulation. Nature Communications, 2018, 9, 1685.	12.8	211
64	Efficacy of weekly administration of paclitaxel and carboplatin for advanced ovarian cancer patients with poor performance status. International Journal of Clinical Oncology, 2018, 23, 698-706.	2.2	7
65	Two cases of recurrent uterine cervical cancer with arterio-enteric fistula treated by femoro-femoral artery bypass in hybrid operation room. International Cancer Conference Journal, 2018, 7, 26-29.	0.5	1
66	Recurrence of uterine myoma after myomectomy: Open myomectomy versus laparoscopic myomectomy. Journal of Obstetrics and Gynaecology Research, 2018, 44, 298-302.	1.3	64
67	Feasibility of laparoscopic surgery for obese patients with uterine corpus cancer. Japanese Journal of Gynecologic and Obstetric Endoscopy, 2018, 34, 159-164.	0.0	O
68	A Case of Recurrent Esophageal Cancer Treated with Concurrent Chemoradiation Therapy in Pregnancy. Case Reports in Obstetrics and Gynecology, 2018, 2018, 1-6.	0.3	1
69	Noninvasive Positive-Pressure Ventilation for Preeclampsia-Induced Pulmonary Edema: 3 Case Reports and a Literature Review. Case Reports in Obstetrics and Gynecology, 2018, 2018, 1-6.	0.3	1
70	Impaired Wnt5a signaling in extravillous trophoblasts: Relevance to poor placentation in early gestation and subsequent preeclampsia. Pregnancy Hypertension, 2018, 13, 225-234.	1.4	13
71	The effect of the type of dietary protein on the development of ovarian cancer. Oncotarget, 2018, 9, 23987-23999.	1.8	11
72	Molecular Pathogenesis of Ovarian Cancer: An Inextricable Maze. , 2018, , 123-134.		1

#	Article	IF	Citations
73	Exome Sequencing Landscape Analysis in Ovarian Clear Cell Carcinoma Shed Light on Key Chromosomal Regions and Mutation Gene Networks. American Journal of Pathology, 2017, 187, 2246-2258.	3.8	104
74	Clonal composition of human ovarian cancer based on copy number analysis reveals a reciprocal relation with oncogenic mutation status. Cancer Letters, 2017, 405, 22-28.	7.2	17
75	Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2017, 18, 1274-1284.	10.7	1,376
76	A Case of Macrolide-Refractory Mycoplasma pneumoniae Pneumonia in Pregnancy Treated with Garenoxacin. Case Reports in Obstetrics and Gynecology, 2017, 2017, 1-4.	0.3	2
77	A case of complete hydatidiform mole with coexistent fetus developing hypertension and acute heart failure. Hypertension Research in Pregnancy, 2017, 5, 20-23.	0.2	0
78	Dual Faces of IFN \hat{I}^3 in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity. Clinical Cancer Research, 2016, 22, 2329-2334.	7.0	309
79	Immune checkpoint inhibition in ovarian cancer. International Immunology, 2016, 28, 339-348.	4.0	122
80	Prediction of taxane and platinum sensitivity in ovarian cancer based on gene expression profiles. Gynecologic Oncology, 2016, 141, 49-56.	1.4	33
81	Establishment of a Novel Histopathological Classification of High-Grade Serous Ovarian Carcinoma Correlated with Prognostically Distinct Gene Expression Subtypes. American Journal of Pathology, 2016, 186, 1103-1113.	3.8	71
82	PD-1/PD-L1 blockage in cancer treatmentâ€"from basic research to clinical application. International Journal of Clinical Oncology, 2016, 21, 447-447.	2.2	10
83	PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. International Journal of Clinical Oncology, 2016, 21, 462-473.	2.2	255
84	Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application. International Journal of Clinical Oncology, 2016, 21, 456-461.	2.2	29
85	Suppression of <i>ABHD2</i> , identified through a functional genomics screen, causes anoikis resistance, chemoresistance and poor prognosis in ovarian cancer. Oncotarget, 2016, 7, 47620-47636.	1.8	28
86	Hepatocyte nuclear factorâ€1β (HNFâ€1β) promotes glucose uptake and glycolytic activity in ovarian clear cell carcinoma. Molecular Carcinogenesis, 2015, 54, 35-49.	2.7	57
87	Invasion of uterine cervical squamous cell carcinoma cells is facilitated by locoregional interaction with cancer-associated fibroblasts via activating transforming growth factor-beta. Gynecologic Oncology, 2015, 136, 104-111.	1.4	21
88	Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. Journal of Clinical Oncology, 2015, 33, 4015-4022.	1.6	924
89	Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor- $\hat{l}^{\circ}B$ to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer. Cancer Research, 2015, 75, 5034-5045.	0.9	439
90	Metabolic alterations caused by $HNF1\hat{l}^2$ expression in ovarian clear cell carcinoma contribute to cell survival. Oncotarget, 2015, 6, 26002-26017.	1.8	47

#	Article	IF	CITATIONS
91	Ovarian clear cell carcinoma meets metabolism; HNF- $1\hat{l}^2$ confers survival benefits through the Warburg effect and ROS reduction. Oncotarget, 2015, 6, 30704-30714.	1.8	44
92	Abstract A25: Dysregulation of MYC via STAT1 promotes tumor progression in serous papillary endometrial cancer. , 2015 , , .		0
93	Epigenetic determinants of ovarian clear cell carcinoma biology. International Journal of Cancer, 2014, 135, 585-597.	5.1	40
94	Epigenetic and genetic dispositions of ovarian carcinomas. Oncoscience, 2014, 1, 574-579.	2.2	13
95	Malignant Transformation of Endometriosis: Underlying Mechanisms. , 2014, , 223-234.		0
96	PD-L1 on Tumor Cells Is Induced in Ascites and Promotes Peritoneal Dissemination of Ovarian Cancer through CTL Dysfunction. Clinical Cancer Research, 2013, 19, 1363-1374.	7.0	196
97	Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer. EMBO Molecular Medicine, 2013, 5, 1051-1066.	6.9	235
98	Laparoscopic pelvic lymphadenectomy in patients with early-stage endometrial cancer. Japanese Journal of Gynecologic and Obstetric Endoscopy, 2013, 29, 291-296.	0.0	0
99	Clinical Management of Ovarian Endometriotic Cyst (Chocolate Cyst): Diagnosis, Medical Treatment, and Minimally Invasive Surgery. Current Obstetrics and Gynecology Reports, 2012, 1, 16-24.	0.8	6
100	The activated transforming growth factorâ€beta signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer. International Journal of Cancer, 2012, 130, 20-28.	5.1	62
101	Ovarian clear cell carcinoma as a stress-responsive cancer: Influence of the microenvironment on the carcinogenesis and cancer phenotype. Cancer Letters, 2011, 310, 129-133.	7.2	37
102	The comprehensive assessment of local immune status of ovarian cancer by the clustering of multiple immune factors. Clinical Immunology, 2011, 141, 338-347.	3.2	70
103	Suppression of Metastatic Murine Ovarian Cancer Cells by Transduced Embryonic Progenitor Cells. Hormones and Cancer, 2010, 1, 291-296.	4.9	3
104	Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling. Cancer Science, 2010, 101, 2658-2663.	3.9	32
105	Ovarian cancer in endometriosis: molecular biology, pathology, and clinical management. International Journal of Clinical Oncology, 2009, 14, 383-391.	2.2	139
106	Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis. Cancer Immunology, Immunotherapy, 2009, 58, 641-652.	4.2	144
107	Activated Local Immunity by CCL19-Transduced Embryonic Endothelial Progenitor Cells Suppresses Metastasis of Murine Ovarian Cancer. Stem Cells, 2009, 28, N/A-N/A.	3.2	42
108	Classification using hierarchical clustering of tumor-infiltrating immune cells identifies poor prognostic ovarian cancers with high levels of COX expression. Modern Pathology, 2009, 22, 373-384.	5 . 5	34

#	Article	IF	CITATIONS
109	Contents of Endometriotic Cysts, Especially the High Concentration of Free Iron, Are a Possible Cause of Carcinogenesis in the Cysts through the Iron-Induced Persistent Oxidative Stress. Clinical Cancer Research, 2008, 14, 32-40.	7.0	259
110	Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104 , $3360-3365$.	7.1	1,308
111	Immortalized ovarian surface epithelial cells acquire tumorigenicity by Acrogranin gene overexpression. Oncology Reports, 2007, , .	2.6	9
112	Trophinin is a potent prognostic marker of ovarian cancer involved in platinum sensitivity. Biochemical and Biophysical Research Communications, 2007, 360, 363-369.	2.1	13
113	LH/hCG action and development of ovarian cancerâ€"A short review on biological and clinical/epidemiological aspects. Molecular and Cellular Endocrinology, 2007, 269, 61-64.	3.2	29
114	Cyclical change of hMSH2 protein expression in normal endometrium during the menstrual cycle and its overexpression in endometrial hyperplasia and sporadic endometrial carcinoma. Cancer, 2002, 94, 997-1005.	4.1	24
115	Human ovarian surface epithelial (OSE) cells express LH/hCG receptors, and HCG inhibits apoptosis of OSE cells via upâ€regulation of insulinâ€like growth factorâ€1. International Journal of Cancer, 2001, 91, 309-315.	5.1	60
116	Prognostic significance of cyclooxygenase-2 in laryngeal squamous cell carcinoma. International Journal of Cancer, 2001, 95, 343-349.	5.1	80
117	Early Invasive Adenocarcinoma of the Fallopian Tube: A Case Report and Review of the Literature. Journal of Obstetrics and Gynaecology Research, 1998, 24, 27-31.	1.3	1
118	Human chorionic gonadotropin (hCG) inhibits cisplatin-induced apoptosis in ovarian cancer cells: Possible role of up-regulation of insulin-like growth factor-1 by hCG., 1998, 76, 571-578.		46
119	Human chorionic gonadotropin (hCG) inhibits cisplatinâ€induced apoptosis in ovarian cancer cells: Possible role of upâ€regulation of insulinâ€ike growth factorâ€1 by hCG. International Journal of Cancer, 1998, 76, 571-578.	5.1	3
120	Ascitic Positive Cytology and Intraperitoneal Metastasis in Ovarian Dysgerminoma. Journal of Obstetrics and Gynaecology Research, 1996, 22, 89-94.	1.3	4
121	Expression of heat shock proteins HSP70 and HSP90 in endometrial carcinomas: Correlation with clinicopathology, sex steroid receptor status, and p53 protein expression., 1996, 77, 330-338.		59
122	Altered expression ofnm23-H1 and c-erbB-2 proteins have prognostic significance in adenocarcinoma but not in squamous cell carcinoma of the uterine cervix. Cancer, 1995, 75, 2523-2529.	4.1	50
123	Peritoneal Papillary Serous Carcinoma Arising in an Infertile Woman during Ovulation-Induction Therapy: Immunohistochemical Expression of LH/hCG Receptors. Gynecologic Oncology, 1995, 56, 470-474.	1.4	16
124	Expression of transforming growth factor-alpha in the normal cervix and in benign and malignant lesions of the uterine cervix. BJOG: an International Journal of Obstetrics and Gynaecology, 1994, 101, 325-329.	2.3	7
125	Expression of c-erbb-2 protein and epidermal growth factor receptor in endometrial carcinomas correlation with clinicopathologic and sex steroid receptor status. Cancer, 1993, 72, 2628-2637.	4.1	50
126	Development of healthy lifestyle consciousness index for gynecological cancer patients. Supportive Care in Cancer, 0, , .	2.2	0